Searched for
NEGMA
Sun Pharma outsmarts peers in terms of shareholders' valueSun has had its fair share of problems but has managed to extricate itself quickly and turn things around.- Wockhardt to Outperform: MacquarieMacquarie has initiated coverage on Wockhardt with an ‘Outperform’ rating and set a target price of Rs 900.
- Wockhardt: Will investors forgive the company?Forget its financial and legal woes, Habil Khorakiwala wants the world to notice that Wockhardt is on the road to recovery.
- Investors unwilling to forgive Wockhardt, promoter for failingsForget its financial and legal woes, Habil Khorakiwala wants the world to notice that Wockhardt is on the road to recovery.
- Wockhardt clocks Rs 565-cr loss in Q4Wockhardt has clocked a net loss of Rs 565.2 crore during Q4 FY10 compared to a net loss of Rs 10.2 crore during the corresponding period o...
- Wockhardt may take forex issue to courtWockhardt is talking tough with banks that have unilaterally terminated their forex contracts with the company ahead of schedule.
- Wockhardt may take forex issue to courtWockhardt is talking tough with banks that have unilaterally terminated their forex contracts with the company ahead of schedule.
- Vetoquinol acquires Wockhardt's veterinary businessFrench veterinary company Vetoquinol has acquired the veterinary business of pharma company Wockhardt, pipping bigger rivals such as Pfizer...
- Wockhardt's German arm sold for Rs 120 crWockhardt has sold its German subsidiary Esparma to another German company, Lindopharm GmbH, a move that is in line with its plan to divest...
- Khorakiwala quits as MD amid Wockhardt debt pileMumbai-based pharma major Wockhardt on Tuesday announced a major organisational change and admitted that it was facing problems in servicin...
- Wockhardt promoters pledge 40% for Rs 350 crThe Khorakiwala family, the promoters of pharmaceutical and biotechnology firm Wockhardt, pledged a 40% stake with financial institutions s...
- Wockhardt may sell 2 foreign armsDrug major Wockhardt is looking for potential buyers for its French subsidiary Negma Laboratories to repay its debt to investors.
- Pharma cos pop European pillDestination Europe seems to be the mantra that Indian pharma companies are following, as the sector ranked second highest in the maximum nu...
- Wockhardt Q1 FY 08 sales up 50 per cent at Rs 786 crorePharmaceutical and bio-tech major Wockhardt Ltd on Monday posted its consolidated sales for the first quarter ended March 31, 2008 at Rs 78...
- Wockhardt acquires US-based Morton GrovePharmaceutical major Wockhardt Ltd has acquired Morton Grove Pharmaceuticals, a liquid generic and specialty dermatology company in the US ...
- Wockhardt buys Morton Grove of US; Q3 net profit down 35%Wockhardt Ltd has acquired Morton Grove Pharmaceuticals, a leading liquid generic and speciality dermatology company in the US having sales...
- Wockhardt eyes $1 billion sales next fiscalWockhardt Hospitals, which has already filed the draft red herring prospectus with SEBI, expects to float an initial public offer (IPO) by ...
- After strong Q1, Ranbaxy reclaims numero uno slotRanbaxy has reclaimed the top slot as the largest pharma company in India from Dr Reddy’s Laboratories.
- Wockhardt gets a leg-up in EuropeWockhardt’s latest acquisition expands its footprint in Europe. Wockhardt will pay $265 million (Rs 1,090 crore) in cash to acquire Negma L...
- Wockhardt buys French co for Rs 1,090 crWockhardt has acquired Negma Laboratories in cash - a deal that would give it access to the European mkt.
Load More- Investors unwilling to forgive Wockhardt, promoter for failings
